truFel HCP

Feline Rhinotracheitis-Calici-Panleukopenia Vaccine

Modified Live Virus

For use in animals only

This product has been shown to be effective for vaccination of healthy cats 8 weeks of age or older against feline rhinotracheitis, calici, and panleukopenia viruses. The duration of immunity for this product has not been established. For more information regarding efficacy and safety data, go to productdata.aphis.usda.gov.

Directions For Use

Aseptically rehydrate with the accompanying diluent. Cats, inject (one) 1 mL dose subcutaneously using aseptic technique. Healthy cats should receive two doses, 3 to 4 weeks apart, except that if the animal is less than 16 weeks of age, the final dose should be given no earlier than 16 weeks of age. The presence of maternal antibody is known to interfere with the development of active immunity in cats and additional boosters will be required in most young animals.

Historically, annual revaccination with a single dose has been recommended for this product. The need for this booster has not been established. For advice on revaccination frequency and annual booster vaccinations, consultation with a veterinarian is recommended. Do not vaccinate pregnant queens.

truFel HCP Caution

In the absence of a veterinarian-client-patient relationship, Federal law prohibits the relabeling, repackaging, resale, or redistribution of the individual contents of this package.

truFel HCP Caution

Store in the dark at 2° to 8°C (35° to 46°F). AVOID FREEZING. SHAKE WELL. Do not mix with other products, except as specified on the label. Use entire contents when first opened. Inactivate all unused contents before disposal. In case of anaphylactoid reaction, administer epinephrine. In case of human exposure, contact a physician.

Neomycin and polymyxin B added as preservatives.

Elanco US Inc., Fort Dodge, IA 50501

Phone: 888-545-5973

VLN/PCN 196/16D1.22

TruFel, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.

© 2021 Elanco or its affiliates.

CPN: 1943031.3